Effect of Short-term Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertriglyceridemia |
Hyeon, Cheol Won
(Department of Internal Medicine, Chung-Ang University College of Medicine)
Choi, Young Hwan (Department of Internal Medicine, Chung-Ang University College of Medicine) Hyun, Seonghyup (Department of Internal Medicine, Chung-Ang University College of Medicine) Kwon, Jee Eun (Department of Internal Medicine, Chung-Ang University College of Medicine) Kim, Eun Young (Department of Internal Medicine, Chung-Ang University College of Medicine) Shin, Seung Yong (Department of Internal Medicine, Chung-Ang University College of Medicine) Lee, Wang-Soo (Department of Internal Medicine, Chung-Ang University College of Medicine) Lee, Kwang Je (Department of Internal Medicine, Chung-Ang University College of Medicine) Kim, Sang-Wook (Department of Internal Medicine, Chung-Ang University College of Medicine) Kim, Tae Ho (Department of Internal Medicine, Chung-Ang University College of Medicine) Kim, Chee Jeong (Department of Internal Medicine, Chung-Ang University College of Medicine) |
1 | Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009;122:962.e1-8. DOI |
2 | Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010;210:35-40. DOI ScienceOn |
3 | Rossner S, Oro L. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate. Atherosclerosis 1981;38:273-282. DOI |
4 | Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(6A):3C-18C. DOI ScienceOn |
5 | Lageder H. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia]. Wien Klin Wochenschr 1980;92:95-101. |
6 | Dick TB, Marples J, Ledermann HM, Whittington J. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia. Curr Med Res Opin 1981;7:489-502. DOI |
7 | Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219. DOI ScienceOn |
8 | Kim MA. Triglyceride and cardiovascular disease. J Lipid Atheroscler 2013;2:1-8. DOI |
9 | Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-458. DOI ScienceOn |
10 | The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000. DOI ScienceOn |
11 | Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-910. DOI ScienceOn |
12 | Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy 2001;21:1145-1149. DOI ScienceOn |
13 | Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861. DOI ScienceOn |
14 | Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15:1993-1999. DOI ScienceOn |
15 | The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574. DOI ScienceOn |
16 | Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002;92:536-541. DOI ScienceOn |
17 | Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol 2001;12:341-348. |
18 | Ansquer JC, Dalton RN, Causse E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008;51:904-913. DOI ScienceOn |
19 | Cho JH, Choi YH, Hyeon CW, et al. Effect of fenofibrate therapy on blood creatinine levels in patients with hypertension and hypertriglyceridemia. J Lipid Atheroscler 2013;2:19-26. DOI |
20 | Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-290. DOI |
21 | Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999;354:219-220. DOI ScienceOn |
22 | Williams AJ, Baker F, Walls J. The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. Br J Clin Pharmacol 1984;18:361-367. DOI ScienceOn |
23 | Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002;92:536-541. DOI ScienceOn |
24 | Angeles C, Lane BP, Miller F, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients:biopsy evidence of tubular toxicity. Am J Kidney Dis 2004;44:543-550. DOI ScienceOn |